Albert Einstein College of Medicine
einsteinmed.eduTotal trials
199
Active
30
Phase 3
10
Total enrollment
213,036
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 7 of 7 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Vaginal estradiol | — | — | — | — | — | 1 | |
| Potassium Citrate Extended Release Oral | — | — | — | — | — | 1 | |
| Potassium Citrate and Citric Acid Oral Solution | — | — | — | — | — | 1 | |
| Diazoxide | — | — | — | — | 3 | ||
| Nicotinic acid | — | — | — | — | — | 2 | |
| Dexamethasone | — | — | — | — | 2 | ||
| Tamsulosin | — | — | — | — | — | 1 |
Next readouts
- 2026-07
- 2026-08
- 2027-04
- 2031-06-30
Top conditions
- Chronic Pain11
- Type 1 Diabetes8
- Type 2 Diabetes7
- HIV7
- Pain7
- Breast Cancer6
- Chronic Kidney Disease5
- Diabetes Mellitus4
Frequently asked questions about Albert Einstein College of Medicine
- How many clinical trials does Albert Einstein College of Medicine have on ClinicalTrials.gov?
- Albert Einstein College of Medicine is listed as the lead sponsor on 199 clinical trials in ClinicalTrials.gov, 30 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Albert Einstein College of Medicine's trials are in Phase 3?
- 10 of Albert Einstein College of Medicine's trials are in Phase 3, spread across 7 active drug programs.
- What therapeutic areas does Albert Einstein College of Medicine focus on?
- Albert Einstein College of Medicine's most-studied conditions on ClinicalTrials.gov are Chronic Pain, Type 1 Diabetes, Type 2 Diabetes, HIV, Pain.
- When are Albert Einstein College of Medicine's next clinical trial readouts?
- Albert Einstein College of Medicine has 4 upcoming primary-completion readouts tracked here; the soonest is “A Pilot Study of Ultra-High-Dose Hypofractionated or Single-Dose Radiotherapy for Intermediate Risk Prostate Cancer”, expected around 2026-07.